Timo Minssen (Former)
51 – 100 of 103
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Patenting Human Genes in Europe: and how it compares to the US and Australia
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Innovation and Intellectual Property Policies in European Research Infrastructure Consortia - PART I: The Case of the European Spallation Source ERIC
(
- Contribution to journal › Article
- 2016
-
Mark
Separating sheep from goats : A European view on the patent eligibility of biomedical diagnostic methods
(
- Contribution to journal › Article
-
Mark
Fighting Falsified Medicines with Paperwork – A Historic Review of Danish Legislation Governing Distribution of Medicines
(
- Contribution to journal › Article
-
Mark
Reconciling IPRs and openness in biobanking
(
- Contribution to journal › Article
-
Mark
Standards, Data Exchange and Intellectual Property Rights in Systems Biology
(
- Contribution to journal › Article
-
Mark
The Industrial Application Requirement for Biotech Inventions in Light of Recent EPO and UK Case Law: A Plausible Approach or a Mere "Hunting Licence"?
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2015
-
Mark
The Evolution of the CJEU’s Case Law on Stem Cell Patents : Context, Outcome and Implications of Case C‑364/13 International Stem Cell Corporation
(
- Contribution to journal › Article
-
Mark
The Impact of Broccoli II & Tomato II on European patents in conventional breeding, GMO’s and Synthetic Biology : The grand finale of a juicy patents tale?
(
- Contribution to journal › Article
-
Mark
Will clinical trial data disclosure reduce incentives to develop new uses of drugs?
(
- Contribution to journal › Article
-
Mark
Life after Myriad: the uncertain future of patenting biomedical innovation and personalised medicine in an international context
(
- Contribution to journal › Article
-
Mark
Enforcing patents in the era of 3D printing
(
- Contribution to journal › Article
-
Mark
IPRs in Biobanking: Risks and Opportunities for Translational Research
(
- Contribution to journal › Article
-
Mark
Standardization, IPRs and open innovation in synthetic biology
2015) p.34-66(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A “ray of hope” for European stem cell patents or “out of the smog into the fog”?: The CJEU decision in C-364/13 and how it compares to recent US developments.(under review)
2015) In Biotechnology Law Report(
- Contribution to journal › Article
-
Mark
Synthetic biology and intellectual property rights: Six recommendations
(
- Contribution to journal › Article
- 2014
-
Mark
Book Review: Drexl, J., Lee, N. (2013). Pharmaceutical Innovation, Competition and Patent Law : A Trilateral Perspective. Edward Elgar Publishing
(
- Contribution to journal › Review (Book/Film/Exhibition/etc.)
-
Mark
The ”opt out” and “opt in” provisions in the Unified Patent Court Agreement – Impact and strategies for European patent portfolios
(
- Contribution to journal › Article
-
Mark
Legal aspects of biobanking as key issues for personalized medicine and translational exploitation
(
- Contribution to journal › Article
- 2012
-
Mark
Assessing the Inventiveness of Bio-Pharmaceuticals under European and US Patent Law - A comparative study with special emphasis on DNA- and protein-related inventions
2012)(
- Thesis › Doctoral thesis (monograph)
-
Mark
The US Supreme Court in Mayo v Prometheus - taking the fire from or to biotechnology and personalized medicine?
(
- Contribution to journal › Article
-
Mark
Standing on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO--Part II1
(
- Contribution to journal › Article
-
Mark
What intent, whose intent and to what extent?: The Knowledge requirement in indirect patent infringement
(
- Contribution to journal › Article
-
Mark
The industrial application requirement for biotech inventions in light of recent EPO & UK case law:: A plausible "hunting license"?"
(
- Contribution to journal › Article
- 2011
-
Mark
US Patent Eligibility in the Wake of Bilski v Kappos: "Business as Usual" in an Age of New Technologies?
(
- Contribution to journal › Article
-
Mark
Standing on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO--Part I
(
- Contribution to journal › Article
-
Mark
Contribution to case law summaries and comments: Tri-lingual
2011)(
- Book/Report › Book
-
Mark
Standing on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO – Part I
(
- Contribution to journal › Article
- 2010
-
Mark
Refusal to supply in the EU pharmaceutical sector under the rule of reason
(
- Contribution to journal › Article
-
Mark
Meanwhile on the Other Side of the Pond: Why Biopharmaceutical Inventions that Were'Obvious to Try'Still Might Be Non-Obvious--Part I
(
- Contribution to journal › Article
- 2009
-
Mark
Meanwhile on the Other Side of the Pond: Why Biopharmaceutical Inventions that Were “Obvious to Try” Still Might Be Non-Obvious – Part I
2009) In Chicago-Kent Journal of Intellectual Property (forthcoming)(
- Contribution to journal › Article
-
Mark
“Restoring the balance: The patentability of DNA-related technology in the US and Europe”
2009) Scholarship speech prepared for the AWAPATENT Foundation for the Promotion of Scientific Research in the Area of Intellectual Property Rights. p.1-10(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
The rule of reason under Article 82 EC After Sot Lelos kai Sia
2009)(
- Working paper/Preprint › Working paper
- 2008
-
Mark
The US Examination of Nonobviousness After KSR v. Teleflex with Special Emphasis on DNA-Related Inventions
(
- Contribution to journal › Article
-
Mark
Es bleibet dabei: Eine schwedische Stellungnahme zur europäischen Debatte über den absoluten Erzeugnisschutz bei der DNA Patentierung
(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar?- Del I (When does US patent law regard a biotechnological invention as complete and useful?)
(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar? - Del II (When does European patent law regard a biotechnological invention as complete and having an industrial application?)
(
- Contribution to journal › Article
-
Mark
Is In re Deuel still the law of the land? The US examination of nonobviousness after KSR v. Teleflex with special emphasis on DNA related inventions
2008) In Historielärarnas Förenings Årsskrift(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar?--Del 1:--Om nyare utvecklingar kring kravet på’industrial application’och’utility’för gen-och proteinrelaterade uppfinningar i USA och Europa
(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar? – Del 2: Om nyare utvecklingar kring kravet på ’industrial application’ och ’utility’ för gen- och proteinrelaterade uppfinningar i USA och Europa
(
- Contribution to journal › Article
-
Mark
Es bleibet dabei: Eine schwedische Stellungnahme zur europäischen Debatte über den absoluten Erzeugnisschutz bei der DNA-Patentierung--Teil 2
(
- Contribution to journal › Article
-
Mark
Es bleibet dabei: Eine schwedische Stellungnahme zur europäischen Debatte über den absoluten Erzeugnisschutz bei der DNA-Patentierung – Teil 1
(
- Contribution to journal › Article
-
Mark
The US Examination of Nonobviousness after KSR vs. Teleflex with Special Emphasis on DNA-Related Inventions
(
- Contribution to journal › Article
-
Mark
Zur Zulässigkeit von Feststellungsklagen im US Lizensrecht nach den Entscheidungen in MedImmune und SanDisk
2008) In GRUR International (Gewerblicher Rechtsschutz und Urheberrecht)(
- Contribution to journal › Article
-
Mark
Standing in the shadows of Brüstle: ordre public & the patentability of human embryonic stem cell technology in Germany and at the EPO
2008) In Historielärarnas Förenings Årsskrift(
- Contribution to journal › Article
- 2007
-
Mark
Res judicata in the court of justice case-law: Balancing legal certainty with legality?
(
- Contribution to journal › Article
-
Mark
Obesvarade frågor rörande patent på datorrelaterade uppfinningar och affärsmetoder? (Unanswered questions concerning patents on computer related inventions and business methods?)
(
- Contribution to journal › Article
-
Mark
Obesvarade frågor rörande patent på datorrelaterade uppfinningar och affärsmetoder?: Reflektioner kring Alain Pompidous brev till Lord Justice Jacob
(
- Contribution to journal › Article
-
Mark
Res judicata i EG –domstolens rättspraxis: en avvägning mellan rättssäkerhet och lagenlighet
(
- Contribution to journal › Article
- 2006
-
Mark
Purpose-bound product patents for human DNA sequences? Discussing scope of protection issues in the light of the German implementation of the Biotech directive
2006) Legal Aspects of Biotechnology in Europe(
- Contribution to conference › Paper, not in proceeding